Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years

Safety of Herpes Zoster Vaccine in the Shingles Prevention Study

(2013) Michael S. Simberkoff   ANNALS OF INTERNAL MEDICINE

Barriers to the Use of Herpes Zoster Vaccine

(2013) Laura P. Hurley   ANNALS OF INTERNAL MEDICINE

Recommended Adult Immunization Schedule: United States, 2013*

(2013)   ANNALS OF INTERNAL MEDICINE

Similar herpes zoster incidence across Europe: results from a systematic literature review

(2013) Sybil Pinchinat et al.   BMC INFECTIOUS DISEASES

Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications

(2013) M. R. Irwin et al.   CLINICAL INFECTIOUS DISEASES

Studying Physician Knowledge, Attitudes, and Practices Regarding the Herpes Zoster Vaccine to Address Perceived Barriers to Vaccination

(2013) Zachary Elkin et al.   CORNEA

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands

(2013) Pieter T. de Boer et al.   VACCINE

Vaccination against herpes zoster in developed countries

(2013) Mélanie Drolet et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules

(2013) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study

(2013) Sinéad M. Langan et al.   PLOS MEDICINE

Herpes Zoster Vaccination in People Aged 50-59 Years

(2012) H.-t. Li et al.   CLINICAL INFECTIOUS DISEASES

Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years

(2012) K. E. Schmader et al.   CLINICAL INFECTIOUS DISEASES

Immune senescence and vaccines to prevent herpes zoster in older persons

(2012) Myron J Levin   CURRENT OPINION IN IMMUNOLOGY

Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases

(2012) Jie Zhang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Herpes Zoster Vaccine and the Incidence of Recurrent Herpes Zoster in an Immunocompetent Elderly Population

(2012) Hung Fu Tseng et al.   JOURNAL OF INFECTIOUS DISEASES

Discussing the Zoster Vaccine: An Interview with Julie Gerberding, President of Merck Vaccines

(2012) Julie Gerberding et al.   Population Health Management

Roundtable on Postherpetic Neuralgia—What, Why, How Long, and What's Next?

(2012) Rafael Harpaz et al.   Population Health Management

Safety of Zostavax™—A cohort study in a managed care organization

(2012) Roger Baxter et al.   VACCINE

Herpes Zoster Vaccination Among Adults Aged 60 Years and Older, in the U.S., 2008

(2011) Peng-jun Lu et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Herpes zoster in Germany: Quantifying the burden of disease

(2011) Bernhard Ultsch et al.   BMC INFECTIOUS DISEASES

Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old

(2011) C. Raina MacIntyre et al.   Human vaccines & immunotherapeutics

Immunogenicity and safety of ZOSTAVAX® approaching expiry potency in individuals aged ≥50 years

(2011) Robert Arnou et al.   Human vaccines & immunotherapeutics

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland

(2011) Thomas D. Szucs et al.   Human vaccines & immunotherapeutics

Safety and tolerability of zoster vaccine in adults ≥60 years old

(2011) Alexander V. Murray et al.   Human vaccines & immunotherapeutics

Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease

(2011) Hung Fu Tseng   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia

(2011) D. Gilden   JOURNAL OF INTERNAL MEDICINE

Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study

(2011) H. F. Tseng et al.   JOURNAL OF INTERNAL MEDICINE

Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine

(2011) Hung Fu Tseng et al.   VACCINE

Zoster vaccine recommendations: The importance of using a clinically valid correlate of protection

(2011) Michael N. Oxman et al.   VACCINE

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium

(2011) Joke Bilcke et al.   VACCINE

Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?

(2011) Joke Bilcke et al.   VACCINE

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

(2011) Joost N. Vermeulen et al.   VACCINE

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

(2011) Jie Zhang et al.   ARTHRITIS RESEARCH & THERAPY

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

(2010) Alies van Lier et al.   BMC HEALTH SERVICES RESEARCH

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life

(2010) Robert W Johnson et al.   BMC Medicine

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

(2010) M. Drolet et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Zoster Vaccine (Zostavax®)

(2010) Mark Sanford et al.   DRUGS & AGING

Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functional Status and Health-Related Quality-of-Life Measures in Older Adults

(2010) Kenneth E. Schmader et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster

(2010) Richard Mills et al.   VACCINE

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium

(2010) L. Annemans et al.   JOURNAL OF MEDICAL ECONOMICS

Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

(2009) S. C. Sutradhar et al.   Clinical and Vaccine Immunology

An Update on the Pharmacological Management of Post-Herpetic Neuralgia and Painful Diabetic Neuropathy

(2009) Che S Zin et al.   CNS DRUGS

Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

(2009) Adriana Weinberg et al.   JOURNAL OF INFECTIOUS DISEASES

Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans

(2009) Ronald R. White et al.   PHARMACOECONOMICS

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales

(2009) A.J. van Hoek et al.   VACCINE

Herpes Zoster and Postherpetic Neuralgia

(2008) Robert W Johnson et al.   DRUGS & AGING

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

(2008) A. GAUTHIER et al.   EPIDEMIOLOGY AND INFECTION

Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine

(2008) M. J. Levin et al.   JOURNAL OF INFECTIOUS DISEASES